Replies to post #3064 on OncoSec Medical Inc (ONCSQ)

[TraderUsa]

ONCS I like this part:

"The data presented were impressive. ImmunoPulse demonstrated a partial or complete response. ImmunoPulse treated patients showed a 68% and 45% percent of treated lesions demonstrated a durable response at three and six months, respectively.

To help our readers get an idea of the importance of these results, Amgen (Nasdaq: AMGN) is developing a treatment for melanoma that is currently in phase III trials. The first results provided by the company showed 16% of trial patients on the engineered virus had a durable response compared with 2% of those on the control therapy GM-CSF."

Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html